The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Reyataz
Synonyms :
atazanavir
Class :
Antiretroviral agents, Protease inhibitors
Brand Name :
Reyataz
Synonyms :
atazanavir
Class :
Antiretroviral agents, Protease inhibitors
Dosage Forms & StrengthsÂ
CapsuleÂ
100mgÂ
150mgÂ
200mgÂ
300mgÂ
Treatment-Naive patients
300mg orally one time a day along with ritonavir 100mg
Note: administer atazanavir 400mg one time a day if ritonavir is not tolerable
Take 400mg once daily along with ritonavir 100mg if efavirenz is administered
Treatment-experienced patients
300mg orally one time a day along with ritonavir 100mg
Note: Administer 400mg one time a day along with 100mg ritonavir if tenofovir disoproxil fumarate (DF) and H2- receptor antagonist is taken
Pregnant patients
Treatment- naive and treatment-experienced
300mg orally one time a day along with ritonavir 100mg
Treatment- experienced during the second or third trimester
Administer 400mg one time a day along with 100mg ritonavir; either tenofovir disoproxil fumarate (DF) or H2- receptor antagonist is taken
It is not recommended if both tenofovir disoproxil fumarate and H2-receptor antagonist are taken
Indication: in the treatment of HIV-1 infection, this is used in combination with antiretroviral drugs
Occupational exposure
Based on recommendations of the US Public Health Service Working Group:
300mg orally one time a day along with 100mg ritonavir for 28 days if tolerable
Nonoccupational Exposure
Based on recommendations of the US CDC: 300mg orally along with 100mg ritonavir one time a day
Dosage Forms & StrengthsÂ
CapsuleÂ
100mgÂ
150mgÂ
200mgÂ
300mgÂ
Powder for reconstitutionÂ
50mgÂ
Oral powder
Treatment- naive and Treatment- Experienced Patients
Children aged 3 months and older
:
Weight 5kg to <15kg: 200mg orally one time a day with ritonavir 80mg
Weight 15kg to <25kg: 250mg orally one time a day with ritonavir 80mg
Capsule
Treatment- naive and Treatment- Experienced Patients
Children of age from 6 years to <18 years:
Weight 15kg to <35kg: 200mg orally one time a day with ritonavir 100mg
Weight of up to 35kg: 300mg orally one time a day with ritonavir 100mg
Treatment-Naive patients intolerable to Ritonavir
Children of age from 13 years to < 18 years:
Minimum of 40kg weight: 400mg orally one time a day
Indication: in the treatment of HIV-1 infection along with antiretroviral agents
Dose Adjustments
Renal dose adjustments
Adjustments are not recommended in the absence of hemodialysis
Hepatic dose adjustments
Treatment-Naive adults
Child-Pugh A (Mild liver impairment): 400mg orally one time a day
Child-Pugh B (Moderate liver impairment): 300mg orally one time a day
Child-Pugh C (Severe liver impairment): not recommended
Refer to adult dosingÂ
It may diminish the effect when combined with phenobarbital by affecting the intestinal/hepatic enzyme CYP3A4 metabolism
atazanavir: they may diminish the serum concentration of hormonal contraceptives
atazanavir: they may diminish the serum concentration of hormonal contraceptives
atazanavir: they may diminish the serum concentration of hormonal contraceptives
atazanavir: they may diminish the serum concentration of hormonal contraceptives
atazanavir: they may diminish the absorption of antacids
atazanavir: they may diminish the absorption of antacids
atazanavir: they may diminish the absorption of antacids
atazanavir: they may diminish the absorption of antacids
atazanavir: they may diminish the absorption of antacids
atazanavir: they may diminish the absorption of magnesium salts
atazanavir: they may diminish the absorption of magnesium salts
atazanavir: they may diminish the absorption of magnesium salts
atazanavir: they may diminish the absorption of magnesium salts
atazanavir: they may diminish the absorption of magnesium salts
by affecting intestinal metabolism, the effect of alfuzosin may be increased
by affecting intestinal metabolism, the effect of atazanavir may be decreased
by affecting intestinal metabolism, the effect of conivaptan may be increased
by affecting intestinal metabolism, the effect of dihydroergotamine may be increased
by affecting intestinal metabolism, the effect of enzalutamide may be increased
by affecting intestinal metabolism, the effect of ergonovine may be increased
by affecting intestinal metabolism, the effect of flibanserin may be increased
by affecting intestinal metabolism, the effect of lomitapide may be increased
by affecting intestinal metabolism, the effect of lovastatin may be increased
by affecting intestinal metabolism, the effect of methylergonovine may be increased
by affecting intestinal metabolism, the effect of naloxegol may be increased
by affecting intestinal metabolism, the effect of eliglustat may be increased
when both drugs are combined, there may be an increased risk of adverse effects 
may increase the level of each other by unknown mechanism
may diminish the serum concentration of PHENobarbital
drospirenone/ethinyl estradiol/levomefolateÂ
may diminish the serum concentration of Hormonal Contraceptives
may diminish the absorption of each other when combined
may diminish the absorption of magnesium salts
etonogestrel/ethinyl estradiolÂ
may diminish the serum concentration of Hormonal Contraceptives
It may enhance toxicity when combined with cholic acid by diminishing the elimination
it decreases the rate of elimination of pidotimod
atazanavir: they may enhance the serum concentration of amiodarone
by affecting intestinal metabolism, the effect of alpelisib may be increased
by affecting intestinal metabolism, the effect of bosentan may be increased
the levels of cabergoline may be increased
by affecting intestinal metabolism, the effect of elacestrant may be increased
when both drugs are combined, the metabolism of paclitaxel increases  
when both drugs are combined, there may be an increased effect of cabozantinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
when both drugs are combined, there may be a reduced level of the serum concentration of atazanavir   
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
CYP3A strong enhancers of the small intestine may reduce the bioavailability of atazanavir
atazanavir increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
atazanavir increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
it increases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
may diminish the serum concentration of buprenorphine
may enhance the serum concentration of elbasvir/grazoprevir
rifampin: they may diminish the serum concentration of atazanavir
may diminish the serum concentration of buprenorphine
it may decrease the serum concentration of Atazanavir
it may decrease the serum concentration of Atazanavir
it may decrease the serum concentration of Atazanavir
it may decrease the serum concentration of Atazanavir
it may decrease the serum concentration of Atazanavir
may increase the serum concentration when both drugs are combined
atazanavir: they may enhance serum concentrations of the of rifabutin
methadone concentration serum may be reduced by atazanavir
may diminish the concentration of serum when combined with atazanavir
may diminish the concentration of serum when combined with atazanavir
may diminish the concentration of serum when combined with atazanavir
may diminish the concentration of serum when combined with atazanavir
may diminish the concentration of serum when combined with atazanavir
It may enhance the levels when combined with tamsulosin by affecting CYP3A4 metabolism
it may enhance the metabolism when combined with oxcarbazepine
atazanavir has the potential to reduce the rate of excretion of idebenone, leading to an elevation in levels of serum
Combining tegafur with atazanavir can reduce tegafur’s metabolism
When loracarbef is used together with atazanavir, the risk or seriousness of nephrotoxicity is enhanced
When domeperidone and atazanavir is used together, this leads to reduction in the domeperidone’s metabolism
When atazanavir is used together with fluconazole, this leads to reduction in the atazanavir metabolism
When atazanavir is used together with cephaloglycin, this leads to increased risk or seriousness of nephrotoxicity
When ponesimod is used together with atazanavir, this leads to enhanced risk or seriousness of bradycardia
When atazanavir is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When cefmenoxime is used together with atazanavir, this leads to enhanced risk or seriousness of nephrotoxicity
When atazanavir is used together with droxicam, this leads to enhanced risk or seriousness of nephrotoxicity
When atazanavir is used together with givinostat, this leads to enhanced risk or seriousness of Qtc prolongation
atazanavir leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
atazanavir leads to a reduction in the rate of excretion of chromous sulfate, which leads to an increased level of serum
atazanavir leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
when metronidazole and atazanavir are combined, their metabolism can be slowed down
atazanavir leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
atazanavir leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
atazanavir leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
When indisulam is used together with atazanavir, this leads to a reduction in atazanavir metabolism
combining atazanavir may lead to a decreased excretion of cholecystokinin
atazanavir: it may decrease the metabolism of caroverine
atazanavir: it may decrease the metabolism of dextropropoxyphene
the metabolism of digitoxin can be diminished when combined with atazanavir
atazanavir's absorption may be reduced by almasilate, resulting in lower serum concentrations and potentially decreased efficacy
when both drugs combine atazanavir will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
cyclophosphamide effect of action increased by affecting enzyme CYP3A4 metabolism.
atazanavir on interacting with brentuximab has its effect increased by altering the intestinal or hepatic CYP3A4 enzyme metabolism.
when both drugs are combined, there may be a reduced metabolism of erlotinib  
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
May enhances the effects of the other by pharmacodynamic synergism
may increase the level by affecting hepatic enzyme CYP3A4 metabolism
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
it increases by affecting the hepatic enzyme CYP3A4 metabolism
relugolix/​estradiol/​norethindroneÂ
it decreases by affecting the hepatic enzyme CYP3A4 metabolism
may increase the serum concentration when it is combined
the rate of excretion of aurothioglucose may be reduced with atazanavir
the rate of metabolism of roxadustat may be reduced
atazanavir, when taken with ixazomib, alters the intestinal/hepatic CYP3A4 enzyme metabolism
it decreases the concentration of hormonal contraceptives in serum
may increase the level by affecting the hepatic enzyme CYP3A4 metabolism
When atazanavir is used together with oliceridine, this leads to enhanced concentration serum of oliceridine
Actions and spectrum:Â
Atazanavir is a protease inhibitor. It acts by preventing the cleavage of Gag-Pol polyprotein that causes the development of noninfectious and immature viral particles
Frequency definedÂ
Dizziness (1-2%)Â
Depression (1-2%)Â
Headache (1-7%)Â
Myalgia (4%)Â
Jaundice (5-9%)Â
Rash (3-21%)Â
Diarrhea (3-11%)Â
Nausea (4-14%)Â
Increase in levels of Creatine phosphokinase (6-11%)Â
Increase in cholesterol (6-25%)Â
Fever (19%)Â
Cough (21%)Â
Increase in total bilirubin (35-49%)Â
Black Box Warning Â
Not listedÂ
Contraindication/Caution:Â
Contraindication:Â
HypersensitivityÂ
Erythema multiformeÂ
Stevens- Johnson syndromeÂ
Pregnancy consideration:Â Â
USFDA pregnancy category: Not assignedÂ
Lactation: Not recommendedÂ
Data about the excretion of atazanavir into breast milk is not availableÂ
Pregnancy category:Â Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus `in either the first or second trimester.Â
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology:Â
Pharmacodynamics:Â
Pharmacokinetics:Â
AbsorptionÂ
The time to attain peak plasma is 2- 3 hourÂ
DistributionÂ
86% of the drug is bound to proteinsÂ
MetabolismÂ
It undergoes hepatic metabolismÂ
Elimination and excretionÂ
13% of the drug is excreted through urine, whereas 79% is excreted through fecesÂ
Half-life:Â
7-8 hourÂ
Administration:Â
Oral powder must be mixed preferably with foods such as yogurt or applesauceÂ
Capsules of atazanavir and ritonavir should be taken with meals.Â
Â
Patient information leafletÂ
Generic Name: atazanavir Â
Why do we use atazanavir?Â
Atazanavir, an antiviral medication, is used in treating HIV by preventing the multiplication of virus in the body.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
